About Ardea Biosciences
Board of Directors
Barry D. Quart, PharmD
President and Chief Executive Officer of Ardea Biosciences, Inc.
Henry J. Fuchs, MD
Executive Vice President and Chief Medical Officer, Onyx Pharmaceuticals, Inc.
Jack S. Remington, MD
Professor of Medicine, Stanford University
Kevin C. Tang
Managing Director, Tang Capital Management
John Poyhonen, MBA
Senior Vice President, Chief Financial and Business Officer, Senomyx, Inc.
Craig Johnson
Vice President and Chief Financial Officer, TorreyPines Therapeutics, Inc.
Biographies
Barry D. Quart, Pharm D
President, Chief Executive Officer and Director
Dr. Quart was elected as a director and appointed as our President and CEO in December, 2006. From 2002 until December, 2006, Dr. Quart was President of Napo Pharmaceuticals, Inc., where he was instrumental in bringing the company public on the London Stock Exchange in July 2006. Prior to Napo, Dr. Quart was Senior Vice President, Pfizer Global Research and Development and the Director of Pfizer's La Jolla Laboratories, where he was responsible for approximately 1,000 employees and an annual budget of almost $300 million. Prior to Pfizer's acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, since 1999. Dr. Quart had joined Agouron in 1993 and was instrumental in the development and registration of nelfinavir (Viracept®), which went from the lab bench to NDA approval in 38 months. Dr. Quart spent over ten years at Bristol-Myers Squibb in both Clinical Research and Regulatory Affairs prior to Agouron and was actively involved in the development and registration of important drugs for the treatment of HIV and cancer, including paclitaxel (Taxol®), didanosine (Videx®), and stavudine (Zerit®). He has a PharmD from University of California, San Francisco.
To return to top click here
Henry J. Fuchs, MD
Executive Vice President and Chief Medical Officer, Onyx Pharmaceuticals, Inc.
Dr. Fuchs has served as one of our directors since November 2001. Since September 2005 Dr. Fuchs has been the Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals, Inc. He served as our Chief Executive Officer from January 2003 until June 2005. Dr. Fuchs joined us as Vice President, Clinical Affairs in October 1996 and was appointed President and Chief Operating Officer in November 2001. From 1987 to 1996, Dr. Fuchs held various positions at Genentech, Inc. where, among other things, he had responsibility for the clinical program that led to the approval for Genentech’s Pulmozyme®. Dr. Fuchs was also responsible for the Phase III development program that led to the approval of Herceptin® to treat metastatic breast cancer. Dr. Fuchs received an MD degree from George Washington University and a BA degree in biochemical sciences from Harvard University.
To return to top click here
Jack S. Remington, MD
Professor, Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine
Dr. Remington has served as one of our directors since October 1996. Dr. Remington currently serves and has served as Professor, Department of Medicine, Division of Infectious Diseases and Geographic Medicine, at the Stanford University School of Medicine and as Chairman of the Department of Immunology and Infectious Diseases at the Research Institute of the Palo Alto Medical Foundation for nearly four decades. In addition, Dr. Remington is a consultant for leading pharmaceutical companies with regard to antibiotic research and development and has served on numerous editorial boards of medical journals. He is a past President of the Infectious Disease Society of America. Dr. Remington is a nationally recognized authority in the field of infectious disease medicine, and received the Gold Medal from the Royal College of Physicians, London, England in 1999 and the 1996 Bristol Award of the Infectious Disease Society of America.
To return to top click here
Kevin C. Tang
Managing Director, Tang Capital Management, LLC
Mr. Tang has served as one of our directors since May 2003. Mr. Tang is the Managing Director of Tang Capital Management, LLC, a life sciences-focused investment company he founded in August 2002. From September 1993 to July 2001, Mr. Tang held various positions at Deutsche Banc Alex. Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm's life sciences research group. Mr. Tang currently serves as a director of Trimeris, Inc. Mr. Tang received a BS degree from Duke University.
To return to top click here
John Poyhonen, MBA
Senior Vice President, Chief Financial and Business Officer, Senomyx, Inc.
Mr. Poyhonen has provided senior-level leadership to a number of top-tier pharmaceutical and biotechnology companies. He is currently the Senior Vice President, Chief Financial and Business Officer of Senomyx, Inc., where he was also the Vice President and Chief Business Officer from 2003 to 2004. From 1996 to 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, a Pfizer company, including Vice President of National Sales, Vice President of Marketing and Vice President of National Accounts. While at Agouron, he oversaw the successful commercial launch of Viracept(R), a protease inhibitor for the treatment of HIV. Mr. Poyhonen received his BA in Marketing from Michigan State University and his MBA from the University of Kansas.
To return to top click here
Craig Johnson
Vice President and Chief Financial Officer, TorreyPines Therapeutics, Inc.
Mr. Johnson has served as one of our directors since June 2008. Since 2004, Mr. Johnson has been the Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. From 1994 to 2004, Mr. Johnson was employed by MitoKor, Inc. and last held the position of Chief Financial Officer and Senior Vice President of Operations. Prior to joining MitoKor, he was a senior financial executive for several early-stage technology companies. From 1984 to 1988, Mr. Johnson worked for the accounting firm Price Waterhouse LLP. He has been actively involved in the Association of Bioscience Financial Officers since 1998. Mr. Johnson received his B.B.A. in accounting from the University of Michigan and is a certified public accountant.
To return to top click here
